Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well dutasteride works in treating patients with
recurrent prostate cancer that did not respond to androgen-deprivation therapy.